Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. by Bani, Daniele et al.
Mario Bigazzi and Emanuela Masini
Daniele Bani, Paola Failli, Maria Grazia Bello, Christoph Thiemermann, Tatiana Bani Sacchi,
in Culture
Nitric Oxide Pathway in Vascular Smooth Muscle Cells−Relaxin Activates the l-Arginine
Print ISSN: 0194-911X. Online ISSN: 1524-4563 
Copyright © 1998 American Heart Association, Inc. All rights reserved.




World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://hyper.ahajournals.org//subscriptions/
is online at: Hypertension  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialHypertensionin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at UNIV DI FIRENZE on September 25, 2012http://hyper.ahajournals.org/Downloaded from 
Relaxin Activates theL-Arginine–Nitric Oxide Pathway in
Vascular Smooth Muscle Cells in Culture
Daniele Bani, Paola Failli, Maria Grazia Bello, Christoph Thiemermann, Tatiana Bani Sacchi,
Mario Bigazzi, Emanuela Masini
Abstract—The peptide hormone relaxin (RLX) has been shown to elicit a powerful vasodilatory response in several target
organs. This response is mediated by the stimulation of intrinsic nitric oxide (NO) generation. The present study was
designed to clarify whether RLX directly promotes the relaxation of vascular smooth muscle cells through stimulation
of NO generation. Vascular smooth muscle cells from bovine aortas were incubated with RLX at concentrations ranging
from 1 nmol/L to 1mmol/L. The expression and activity of NO synthase, production of NO, and the intracellular levels
of cGMP and Ca21 were determined. The cell morphology and signal transduction mechanisms of these bovine aortic
smooth muscle cells in response to RLX were also studied. RLX stimulated the expression of immunoreactive inducible
NO synthase and increased significantly and in a concentration-related fashion inducible NO synthase activity, NO
generation, and intracellular cGMP levels. Concurrently, RLX significantly decreased cytosolic Ca21 oncentrations and
caused changes in cell shape and the actin cytoskeleton that were consistent with cell relaxation. The signal transduction
mechanisms leading to the enhanced expression of inducible NO synthase protein and activity caused by RLX involve
the activation of tyrosine kinase, phosphatidylcholine–phospholipase C, and the transcription factor nuclear factor-kB,
similar to bacterial endotoxins and proinflammatory cytokines. This study suggests that RLX is an endogenous agent
capable of regulating vascular tone by activation of theL-arginine–NO pathway in vascular smooth muscle cells.
(Hypertension. 1998;31:1240-1247.)
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Relaxin is a peptide hormone of'6 kDa that is predom-inantly produced by the ovaries and is best known for its
actions on the female reproductive system.1 Recently, evi-
dence has been accumulating that RLX has additional multi-
ple effects on organs other than the reproductive ones. In
particular, previous research in our laboratory has shown that
RLX exerts a powerful effect on blood vessels, causing
vasodilation in the uterus, mammary gland, pigeon crop sac,
mesocecum, and coronary system.2–8 Our findings fit well
with those of other authors that RLX also decreases blood
pressure in spontaneously hypertensive rats.9,10 All of the
above findings support the idea that RLX is effective in
reducing vascular tone. Concerning the mechanism of action
of RLX on its target organs, our studies of coronary vessels in
the isolated, perfused rat and guinea pig heart7,8 have shown
that the vasodilatory action of RLX is mediated by stimula-
tion of endogenous production of NO, which is a powerful
vasorelaxant.11,12 It is worth noting that stimulation of intrin-
sic NO production is also involved in the response to RLX in
different cells, such as rat and guinea pig serosal mast cells,13
human and rabbit platelets,14 and mammary adenocarcinoma
MCF-7 cells.15
There is general agreement that the vasodilatory action of
NO is primarily an endothelium-dependent process. In fact,
endothelial cells contain the constitutive, Ca21/calmodulin-
dependent isoform of NOS (ie, eNOS) that continuously
generates small quantities of NO. In turn, endothelium-
derived NO is responsible for the physiological regulation of
basal vascular tone, being able to diffuse readily into the
SMCs of the vascular wall, where it activates multiple
cellular mechanisms that ultimately result in cell relax-
ation.16–18Other studies have shown that VSMCs are also sites
for basal formation of NO due to the presence of the
inducible, Ca21/calmodulin-independent NOS (ie, iNOS) iso-
form.19–24 Indirect evidence for NO production by VSMCs
also comes from the results of studies reporting that oxyhe-
moglobin, a potent inactivator of NO, causes SMC contrac-
tion in endothelium-denuded vascular rings25–29 and that in
vitro incubation of VSMCs together with platelets, which are
extremely sensitive to the antiaggregatory action of NO,
results in an inhibition of platelet aggregation.30 In VSMCs,
iNOS can be upregulated by damage or removal of the
endothelium31,32 as well as by endotoxins, such as bacterial
LPS, and cytokines.19,22,33–39
The intracellular signal transduction mechanisms involved
in the expression of iNOS are not completely known. Studies
in macrophages, in which the regulation of iNOS expression
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has been more extensively studied, have shown that induction
of iNOS by LPS or cytokines involves the activation of
transcription factor NF-kB,40–42 which has been shown to
have a binding site on the iNOS gene promoter.42 NF-kB is
normally stored in the cytoplasm in an inactivated state by
binding with its inhibitor protein IkB-a. Proinflammatory
cytokines promote phosphorylation of IkB-a and its dissoci-
ation from NF-kB, as well as proteolytic degradation of
IkB-a through a specific IkB-a protease, thus leading to
NF-kB activation.40,43 Of note, NF-kB activation in response
to cytokines has been shown to be under the control of
different signal transduction effectors, including tyrosine
kinase44 and PC-PLC,45 both of which are also known to
upregulate iNOS expression.46,47 Moreover, cytokine-stimu-
lated cells produce reactive oxygen radicals40 that are able to
activate NF-kB.40,48 Through all of the aforementioned path-
ways, cells are prompted to express iNOS protein and to
generate NO.
The present study was designed to evaluate whether RLX
directly promotes the relaxation of SMCs from the vascular
wall through activation of the NO pathway, and if so, to
verify whether the signal transduction events in response to
RLX include the activation of tyrosine kinase or NF-kB.
Methods
Materials
Highly purified porcine RLX (2500 to 3000 U/mg), prepared
according to Sherwood and O’Byrne,49 was the generous gift of Dr
Sherwood. Dulbecco’s modified essential medium (DMEM) and
fetal calf serum (FCS) for cell culture were purchased from Bio-
chrom, and tissue culture plastic ware was from Costar. Antibiotics
for cell culture, trypsin solution, HEPES buffer, NADPH1, EGTA,
EDTA, sulfanilamide,N-(1-naphthyl)ethylenediamine dihydrochlo-
ride, DTT, calmodulin (free base),Escherichia coliLPS endotoxin,
cycloheximide, D609, PDTC, and TPCK were from Sigma Chemical
Co. Tyrphostin AG126 was from Calbiochem Novabiochem. Bovine
thrombin was from Boehringer. [3H]L-Arginine and the radioimmu-
noassay kit for125I-labeled cGMP were from Amersham. BSA,
trichloroacetic acid (TCA), L-NMMA, NaNO2, and trifluoperazine
were from Sigma-Aldrich. Isobutyl methylxanthine (IBMX) was
from Aldrich. Stock solutions of IBMX were prepared in 0.1N
NaOH and then diluted in Krebs buffer.L-Arginine HCl was from
Ultrafine Chemicals Ltd. Fura 2-AM and Pluronic F127 were from
Molecular Probes.S-Nitroso-N-acetylpenicillamine (SNAP) was
from Tocris Cookson. Recombinant murine IFN-g was
from PharMingen.
Cell Culture
SMCs from bovine aortas were isolated as described previously.30
The choice of VSMCs of bovine origin was motivated by the fact
that these cells retain a distinct muscular phenotype in in vitro
culture, including the ability to produce NO,30 and that porcine RLX
has been found to be active in cattle heifers in vivo.50 Smooth muscle
tissue strips were explanted from bovine aortas and placed in
tissue-culture flasks. The tissue strips were then incubated in DMEM
plus 10% FCS until the SMCs, which had spread from the explants,
reached confluence. The explants were removed; the SMCs were
detached with 0.05% wt/vol trypsin for 20 seconds and then
subcultured in DMEM supplemented with 10% FCS (together with
100 IU/mL of penicillin and 100mg/mL of streptomycin) in a
humidified atmosphere of 95% air and 5% CO2 at 37°C. The cells
were used between the 4th and 10th passages in culture. The cells
were released from the culture plates by treatment with 0.5% trypsin
in PBS containing 0.03% EDTA for 5 minutes and allowed to seed
for 24 hours before being used for the experiments. At the beginning
of the experiments, the medium was replaced with fresh medium
alone (controls) or medium with RLX at concentrations ranging from
1 nmol/L to 1 mmol/L unless specified otherwise. The cells were
grown for 24 hours before being processed for functional and
morphological assays unless specified otherwise. Cell viability was
assayed by the trypan blue exclusion test before and after incubation
with either medium alone or medium with 1mmol/L RLX. The
percentage of viable cells did not differ significantly in the various
assays performed (95% before incubation, 97% after 24 hours with
medium alone, and 96% after 24 hours of medium with RLX). The
absence of endotoxin contamination in the distilled water of the
solutions used and the culture medium was evaluated by theLimulus
amebocyte lysate assay (E-toxate, Sigma) as described previously.51
Electron Microscopy
To verify that BASMCs had maintained a distinct SMC phenotype
along with successive culture passages, electron microscopy of the
cells was performed before and after the experimental period. Cells
grown over cellulose discs (Millicell HA, Millipore) placed into the
wells of a 24-well plate were fixed in cold 4% glutaraldehyde in 0.1
mol/L sodium cacodylate buffer, pH 7.4, for 3 hours at room
temperature and postfixed in 1% OsO4 in 0.1 mol/L phosphate
buffer, pH 7.4, for 1 hour at 4°C. They were then dehydrated in
graded acetone, passed through propylene oxide, and embedded in
Epon 812. Ultrathin sections were stained with uranyl acetate and
alkaline bismuth subnitrate and examined under a Siemens Elmiskop
102 electron microscope at 80 kV.
Evaluation of NOS Activity
NOS activity was determined in cell homogenates by measuring the
conversion of [3H]L-arginine to [3H]L-citrulline according to Mollace
et al52 with minor modifications. In brief, 106 BASMCs were seeded
into six-well plates, allowed to grow to subconfluence, and then
cultured in 2 mL of culture medium in the absence (controls) or
presence of RLX at the noted concentrations and times of exposure.
In some cultures, the NOS inhibitor L-NMMA (100mmol/L) was
added to the medium together with RLX (1mmol/L). After they were
washed, the cells were homogenized with an UltraTurrax Labsonic
1510 homogenizer (Ing Terzano and Co) in HEPES buffer
(20 mmol/L, pH 7.2) containing 0.2 mol/L sucrose, 1 mmol/L
EDTA, and 1 mmol/L DTT. Part of the cell homogenates was used
for determination of total NOS activity. The samples (340mL) were
added with 60mL of a medium of the following composition:
13.2 mmol/L NADPH1, 3 mmol/L CaCl2, 10mg/mL calmodulin, 1.3
mol/L L-arginine, and 32mCi/mL [3H]L-arginine. After 60 minutes
of incubation at 37°C, the mixture was loaded onto 3-mL Dowex AG
50WX-8 (Na1 form, Sigma) columns, eluted with 1 mL of HEPES
buffer, and then washed with 5 mL of distilled water. The [3H]L-
citrulline obtained by enzyme activity was measured with a
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b-counter (Packard), and the ratio between labeled citrulline and
milligrams of protein was taken as NOS activity. The protein
concentration was measured spectrophotometrically in the homoge-
nates with the Bradford reagent53 with BSA as the standard. Another
portion of the cell homogenates was used to determine the activity of
Ca21/calmodulin-independent iNOS. The homogenates (340mL)
were added to 60mL of incubation medium as described above but
without Ca21 and calmodulin and containing 6.6 mmol/L EGTA and
the calmodulin inhibitor trifluoperazine (660mmol/L). The activity
of constitutive, Ca21/calmodulin-dependent NOS (ie, cNOS) was
determined from the difference between the values of labeled
citrulline produced in the presence of Ca21 nd calmodulin and those
produced in the absence of Ca21 and calmodulin and in the presence
of EGTA and trifluoperazine, as described by Salter et al.54
Evaluation of NO Production
This step was performed by measuring the accumulation of nitrite
(ie, NO2-), a stable end product of NO metabolism, in the supernatant
of BASMCs. The amount of nitrite was determined spectrophoto-
metrically by the Griess reaction adapted for a 96-well plate reader.55
In brief, 100mL of sample culture medium was added to 100mL of
Griess reagent (1% sulfanilamide and 0.1%N-[1-naphthyl]ethylen-
diamine in 5% phosphoric acid). The optical density at a wavelength
of 546 nm was measured with a Molecular Devices microplate
reader. Nitrite concentrations in the supernatants were calculated by
comparison with standard concentrations of NaNO2 dissolved in the
culture medium. The values are expressed as nanomoles of nitrite per
milligram of protein. The protein concentrations were determined
according to Bradford.53
A first series of experiments was carried out to evaluate the
time-course response of BASMCs to RLX. The cells were seeded
into 24-well plates at density of 53104 cells per well, allowed to
grow to subconfluence, and then incubated for 4, 24, or 96 hours in
1 mL of medium alone (controls), medium with RLX added
(1 mmol/L), or medium with RLX (1 mmol/L) plus L-NMMA
(100 mmol/L).
A second series of experiments was carried out to compare the
effects of authentic RLX with those of inactivated RLX, obtained
according to the method of Büllesbach and Schwabe.56 In brief, 1 mg
of porcine RLX was dissolved in 0.1 mol/L borate buffer, pH 8.9,
with a 10-fold molar excess of 1,2-cyclohexanedione (Sigma), which
reacts specifically with arginine residues57 and thus modifies the
receptor interaction site of the RLX molecule. Excess reagent was
removed by dialysis against distilled water. The BASMCs were
seeded into 24-well plates at a density of 53104 cells per well,
allowed to grow to subconfluence, and then incubated in 1 mL of
medium alone (controls), medium with RLX added at concentrations
ranging from 1 nmol/L to 1mmol/L, or medium with inactivated
RLX at concentrations ranging from 1 nmol/L to 1mmol/L. Parallel
cultures were carried out in medium with L-NMMA (100mmol/L) in
the absence or presence of RLX (1 nmol/L and 1mmol/L).
A third series of experiments was carried out to analyze the
signal transduction pathway underlying NO production in
BASMCs. The cells were seeded into 24-well plates at a density
of 53104 cells per well, allowed to grow to subconfluence, and
then incubated for 24 hours in 1 mL of culture medium in the
absence (controls) or presence of RLX (1mmol/L). For positive
controls, parallel experiments were done with LPS (1mg/mL)
plus IFN-g (10 IU/mL) as iNOS inducers. In some of the above
cultures, drugs acting at different levels of the signal transduction
pathways leading to the induction of iNOS were added to the
culture medium together with RLX or LPS plus IFN-g by
following a protocol that had been used previously for similar
purposes.47 The drugs used were (1) cycloheximide (0.3mg/mL),
which prevents the expression of iNOS by interfering with protein
synthesis21; (2) tyrphostin AG126 (10mmol/L), a tyrosine kinase
inhibitor58; (3) D609 (30mg/mL), an inhibitor of PC-PLC45; (4)
rotenone (30mmol/L), an antioxidant drug that prevents the
formation of reactive oxygen radicals that are generated by cells
after cytokine stimulation and which are able to activate NF-kB40;
(5) PDTC (25mmol/L), an inhibitor of NF-kB activation40,41; and
(6) TPCK (30 mmol/L), an inhibitor of IkB-a protease,59 an
enzyme that is needed for proteolytic degradation of IkB-a,
which binds to and inactivates NF-kB.60 (A representative dia-
gram of the signal transduction events involved in iNOS induction
and the interfering drugs is shown in Figure 1.)
Evaluation of cGMP
cGMP is known to be a mediator of the cell response to NO.16 To
ascertain whether intracellular cGMP undergoes changes in
BASMCs after RLX treatment, 53104 cells were seeded into 24-well
plates, allowed to grow to subconfluence, and then cultured for 24
hours in 1 mL of culture medium in the absence (controls) or
presence of RLX at concentrations ranging from 1 nmol/L to
1 mmol/L. In some cultures, L-NMMA (100mmol/L) was added to
the culture medium together with RLX (1mmol/L). One hour before
the end of the experiments, IBMX (10mmol/L) was added to the cell
cultures to inhibit phosphodiesterase activity. On incubation with the
Figure 1. Diagram illustrating the signal transduction
pathways involved in iNOS induction and inhibitory
drugs that act at different steps (double-slashed
arrows).
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different agents, supernatants were removed and the BASMCs
treated with 500mL of 5% TCA. After extraction of TCA with 0.5
mol/L tri-n-octylamine dissolved in 1,1,2,-trichlorotrifluoroethane,
the samples were acetylated with acetic anhydride,61 and the amounts
of cGMP in the aqueous phase were measured by radioimmunoas-
say.62 The values are expressed as femtomoles of cGMP per
milligram of protein. The protein concentrations were determined
according to the method of Bradford.53
Determination of [Ca21]i
Because intracellular free Ca21 is known to be involved in the
regulation of SMC contraction,63 we aimed at determining whether
RLX affects [Ca21]i in BASMC monolayers by using the fluorescent
Ca21 indicator fura 2-AM.64 In these experiments, [Ca21]i was
determined in individual BASMCs by a digital video imaging
method, as described previously.65 In brief, BASMCs were grown on
round glass coverslips to confluence. The cells were then cultured for
24 hours in 2 mL of medium without FCS and in the absence
(controls) or presence of RLX at concentrations of 1 nmol/L or
1 mmol/L. The cells were incubated with fura 2-AM (10mmol/L)
and Pluronic F127 (15%) for 30 minutes at room temperature. [Ca21]i
was measured in fura 2–loaded cells in HEPES-NaHCO3 buffer
containing 140 mmol/L NaCl, 3 mmol/L KCl, 0.5 mmol/L NaH2PO4,
12 mmol/L NaHCO3, 1.2 mmol/L MgCl2, 10 mmol/L HEPES,
1 mmol/L CaCl2, and 10 mmol/L glucose, pH 7.4. Fluorescence
images were collected with a CCD video camera at two excitation
wavelengths (340 and 380 nm) and emission at 510 nm with the
Magiscan image analysis system (Applied Imaging). Image ratios
(340 nm/380 nm) were obtained every 3 seconds on a pixel-to-pixel
basis after subtraction of the background. After recording the basal
fluorescence value, thrombin at a final concentration of 3 IU/mL was
added directly to the perfusion chamber, and the time course of the
increase in [Ca21]i induced by the agonist was analyzed for at least
6 minutes. Calibration curves were constructed as described.65 In
some experiments, the NO donor SNAP (100mmol/L) was added to
the perfusion chamber and incubated for 5 minutes before the
addition of thrombin.
Immunocytochemistry
BASMCs were grown on glass coverslips placed into 24-well plates
until subconfluence. The cells were then incubated for 24 hours in 1
mL of culture medium in the absence (controls) or presence of RLX
(1 mmol/L) or LPS (1mg/mL) plus IFN-g (10 IU/mL). In some of the
above cultures, cycloheximide (0.3mg/mL) was added to the
medium. After incubation, some specimens were fixed in 4%
formaldehyde in PBS for 10 minutes at room temperature, washed,
and then immunolabeled with rabbit polyclonal anti-iNOS antibodies
(Calbiochem; working dilution, 1:250). Other specimens were fixed
in 50% acetone in ethanol for 10 minutes at 4°C, washed in PBS, and
immunolabeled with mouse monoclonal anti–smooth muscle actin
antibodies (Sigma; working dilution, 1:500). The immune reaction
was revealed by FITC-labeled goat anti-rabbit (Sigma; working
dilution, 1:40) or anti-mouse (Sigma; working dilution, 1:30) immu-
noglobulins. The immunostained sections were mounted in Gel/
Mount (Biomeda) and then observed and photographed under a Zeiss
Axioskop UV-light microscope (Carl Zeiss).
Statistical Analysis
The data are expressed as mean6SEM. The distribution of the
measured values was assessed to be gaussian. Statistical analysis was
performed by either one-way ANOVA followed by the Student-
Newman-Keuls multiple-comparison test or two-way ANOVA. Cal-
culations were carried out with the GraphPad Prism 2.0 statistical
program (GraphPad Software). A value ofP$0.05 was considered
significant.
Results
Electron microscopic examination of BASMCs showed that
these cells have a distinct muscular phenotype. The cells were
thicker in the central portion, in which the nucleus and the
majority of organelles are located, than at the periphery of the
cytoplasm. The organelles consisted mainly of mitochondria
and vesicles of smooth endoplasmic reticulum. Glycogen
particles were also seen. Bundles of myofilaments were
present along the cell periphery beneath the plasma mem-
brane. Myofilaments were intermingled with typical dense
bodies and converged toward dense plaques that adhered to
Figure 2. Representative electron photomicrograph of a
BASMC showing a distinct muscular phenotype. Cytoplasm
contains bundles of myofilaments (arrows). Dense bodies
located within bundles and dense plaques at cell boundaries are
also shown (arrowheads). Magnification 39000; bar51 mm.
Figure 3. Effects of RLX on Ca21/calmodulin-independent iNOS
activity in BASMC homogenates as evaluated by conversion of
[3H]L-arginine to [3H]L-citrulline. RLX stimulated NOS activity at
every concentration assayed. This effect of RLX was abrogated
by L-NMMA. a, Untreated cells; b, RLX 1 nmol/L; c, RLX 10
nmol/L; d, RLX 100 nmol/L; e, RLX 1 mmol/L; and f, RLX
1 mmol/L1L-NMMA. Data are expressed as mean6SEM of 6
wells from 3 independent experiments. Significance of differ-
ences (one-way ANOVA): a versus b, NS; a versus c, P,0.05; a
versus d and e, P,0.01; and f versus e, P,0.001.
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the inner aspect of the plasma membrane (Figure 2).
BASMCs sampled at the beginning and the end of the
experimental period showed a similar ultrastructural pheno-
type. RLX treatment did not cause apparent changes in the
electron microscopic features of BASMCs.
The citrulline conversion assay (Figure 3) showed that
BASMCs exhibit basal Ca21/calmodulin-independent NOS
activity. With RLX treatment, an increase in Ca21/calmodu-
lin-independent NOS activity was observed at every RLX
concentration assayed. This increase was statistically signif-
icant at RLX concentrations of 10 nmol/L (P,0.05) or higher
(P,0.01). This effect of RLX was abrogated by the addition
of the NOS inhibitor L-NMMA to the cultures (P,0.001).
The Ca21/calmodulin-dependent NOS activity was virtually
absent in the BASMCs, as judged by the almost complete
correspondence of the values of NOS activities obtained in
the presence or absence of Ca21 nd calmodulin (data not
shown).
Immunocytochemistry also showed that RLX markedly
increased the expression of iNOS by BASMCs. A similar
effect was obtained by treatment of BASMCs with LPS plus
IFN-g, which are well-known iNOS inducers. These effects
were abrogated by cycloheximide (Figure 4).
In keeping with the above findings, RLX significantly
increased the accumulation of nitrite, the stable end product
of NO, in BASMC supernatants. Time-course determination
of nitrite content (Figure 5) showed that the RLX-induced
increase in nitrite was already appreciable after 4 hours of
incubation and became even more elevated after 24 and 96
hours of incubation (P,0.0001). Addition of L-NMMA
together with RLX abrogated the effect of RLX (P,0.0001).
The RLX-induced increase in nitrite in BASMC supernatants,
evaluated after a 24-hour incubation (Figure 6), was concen-
tration related (P,0.0001). On the other hand, incubation of
BASMCs with inactivated RLX failed to induce any increase
in nitrite in the cell supernatants (P,0.0001). Incubation of
BASMCs with RLX in the presence of L-NMMA resulted in
nearly complete abolition of nitrite formation in the cell
supernatants (P,0.0001). The nitrite accumulation induced
by RLX was prevented by drugs that interfere with intracel-
Figure 4. Immunocytochemical expression of iNOS in BASMCs.
A, No treatment; B, RLX 1 mmol/L; C, LPS 1 mg/mL plus IFN-g
10 IU/mL; and D, RLX 1 mmol/L plus cycloheximide 0.3 mg/mL.
In untreated cells, immunoreactive iNOS was mainly located
around the nucleus, and the cytoplasm is weakly stained. In
both RLX-treated and LPS plus IFNg–treated cells, iNOS immu-
noreactivity was intense in the perinuclear area as well as in the
remaining cytoplasm. Addition of cycloheximide with RLX
strongly reduced iNOS immunoreactivity. Magnification 3300;
bar520 mm.
Figure 5. Effects of RLX (1 mmol/L) on NO production as evalu-
ated by determination of nitrite in BASMC supernatants after
different incubation times. Compared with untreated cells (E),
RLX (L) significantly increased nitrite amounts at every time
assayed. This effect of RLX was abrogated by L-NMMA (l).
Data are expressed are mean6SEM of 12 wells from 3 indepen-
dent experiments. Significance of differences (two-way ANOVA):
P,0.0001.
Figure 6. Effects of authentic RLX (L) and inactivated RLX (‚)
on NO production as evaluated by determination of nitrite con-
tents in BASMC supernatants after a 24-hour incubation. RLX
significantly increased nitrite amounts in a dose-related fashion,
whereas inactivated RLX had no effect. L-NMMA (l) strongly
depressed nitrite generation and abolished the effect of RLX.
Data are expressed are mean6SEM of 12 wells from 3 indepen-
dent experiments. Significance of differences (two-way ANOVA):
P,0.0001.
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lular signal transduction events (Figure 7), such as the protein
synthesis inhibitor cycloheximide (P,0.001), the tyrosine
kinase inhibitor tyrphostin AG126 (P,0.005), the PC-PLC
inhibitor D609 (P,0.005), or the NF-kB activation inhibitors
rotenone (P,0.005), PDTC (P,0.001), and TPCK
(P,0.001). The effect of RLX on NO production by
BASMCs, as well as the effects of combined administration
of RLX and drugs that interfere with signal transduction,
were nearly similar to those obtained by using LPS plus
IFN-g in the place of RLX (Figure 7).
Treatment with RLX also caused a concentration-related
elevation in intracellular cGMP levels (Figure 8) in a fashion
that closely paralleled iNOS activity and NO production.
These differences reached statistical significance with an
RLX concentration of 10 nmol/L or greater (P,0.001).
Addition of L-NMMA to the culture medium together with
RLX resulted in significant inhibition of the RLX-induced
rise in cGMP (P,0.001).
Pretreatment of BASMCs with RLX significantly inhibited
the rise in [Ca21]i induced by thrombin (Figure 9). In fact,
stimulation with thrombin of BASMCs not treated with RLX
caused a marked elevation of [Ca21]i that started 250 to 300
seconds after the addition of thrombin. Treatment of the cells
with RLX before stimulation with thrombin resulted in a
marked reduction of the [Ca21]i rise at an RLX concentration
of 1 nmol/L and a complete inhibition of the [Ca21]i rise at a
concentration of 1mmol/L, as well as increased latency
between the application of thrombin and the [Ca21]i response.
Similar inhibition of the [Ca21]i increase was obtained by
adding the NO donor SNAP (100mmol/L) just before
thrombin (data not shown).
Immunocytochemical staining of BASMCs with anti-actin
antibodies showed that the cell shape and distribution pattern
Figure 10. A, Untreated cells are polyhedral and show immu-
nofluorescent actin concentrated mainly around the nucleus. B,
Cells treated with RLX (1 mmol/L) are mostly fusiform, with long
cytoplasmic processes and immunofluorescent actin almost ho-
mogeneously distributed throughout the cytoplasm. Magnifica-
tion 3300; bar520 mm.
Figure 7. Effects of RLX (1 mmol/L) and of LPS (1 mg/mL) plus
IFN-g (10 IU/mL), alone or in combination with drugs that inter-
fere with signal transduction, on NO production as evaluated by
determination of nitrite contents in BASMC supernatants. Com-
pared with untreated cells (open bars), RLX (hatched bars) as
well as LPS plus IFN-g (filled bars) significantly increased nitrite
formation. These effects were abrogated by addition of the dif-
ferent inhibitory drugs assayed. Data are expressed are
mean6SEM of 12 wells from 3 independent experiments. Signif-
icance of differences (one-way ANOVA): b versus a, P,0.01;
c versus a, P,0.001; RLX versus RLX1inhibitory drugs,
*P,0.01; no asterisk, P,0.001; LPS plus IFN-g versus LPS plus
IFN-g 1 inhibitory drugs, P,0.001.
Figure 8. Effects of RLX on intracellular cGMP amounts in
BASMCs. RLX causes a concentration-related increase in cGMP
levels. This effect of RLX was inhibited by L-NMMA. a,
Untreated cells; b, RLX 1 nmol/L; c, RLX 10 nmol/L; d, RLX 100
nmol/L; e, RLX 1 mmol/L; and f, RLX 1 mmol/L1L-NMMA. Data
are expressed as mean6SEM of 12 wells from 3 separate
experiments. Significance of differences (one-way ANOVA): a
versus b, NS; a versus c, d, and e, P,0.001; and f versus e,
P,0.001.
Figure 9. Effects of RLX at different concentrations on the rise
in [Ca21]i levels evoked by thrombin in BASMCs as evaluated
by digital video imaging. Traces are the mean of at least 20 sin-
gle responses measured in individual fura 2–loaded BASMCs.
Untreated cells, continuous line; 1 nmol/L RLX, filled circles; and
1 mmol/L RLX, open circles. Thrombin (3 U/mL) was adminis-
tered at the time indicated by the arrow.
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of the actin cytoskeleton underwent distinct changes after
RLX treatment (Figure 10). The BASMCs not treated with
RLX were polyhedral, with rare, short cytoplasmic processes.
Actin immunoreactivity was concentrated in the central part
of the cells, thus masking the nucleus, and in “stress fibers”
reaching the cell periphery. Conversely, the RLX-treated
cells were mostly elongated, with a spindle or stellate shape
and long cytoplasmic processes. Actin immunoreactivity was
almost homogeneously distributed throughout the cytoplasm,
and the nucleus was easily visible.
Discussion
The present study shows that RLX directly activates the
L-arginine–NO pathway in arterial SMCs in culture. More-
over, RLX induces changes in cell shape and the actin
cytoskeleton that are consistent with cell relaxation. This
finding agrees with our previous reports that RLX is a
powerful vasodilatory agent favoring the perfusion of target
organs2–8 and with the findings of other authors that RLX
decreases blood pressure in hypertensive rats.9,10 The present
study also shows that RLX increases intracellular cGMP
levels in a concentration-related fashion. This effect of RLX
is likely a consequence of the stimulation of NO production
by this hormone. In fact, NO binds to the heme iron of soluble
guanylate cyclase and thereby activates the synthesis of
cGMP.16,17,25In turn, increased production of cGMP plays an
important role in vasorelaxation, since it is accompanied by a
decrease in [Ca21]i in VSMCs, which ultimately results in cell
relaxation.16–18 In BASMCs, RLX inhibits the agonist-acti-
vated increase in cytosolic Ca21 and induces changes in cell
shape and the actin cytoskeleton that are consistent with cell
relaxation. Of note, a similar effect of RLX on cell shape has
also been observed in uterine SMCs.66 The response of
BASMCs to RLX seems to be specific, because substitution
of authentic RLX with inactivated RLX failed to result in a
cell response in terms of increased NO production.
The present study also shows that the signal transduction
mechanisms leading to the induction of iNOS and the
enhanced formation of NO in BASMCs stimulated by RLX
involve the activation of the transcription factor NF-kB,
likely mediated through tyrosine kinase, PC-PLC, and oxy-
gen free radicals. These mechanisms are similar to those
activated in the same cells by well-known iNOS inducers,
such as LPS and IFN-g, and appear to be quite similar to
those operative in macrophages on activation by endotoxins
and cytokines.40–42,45–47
The concentrations of RLX found by us to be effective in
stimulating the response of BASMCs are higher than those
measured in bovine plasma.67 Nevertheless, the possibility
that RLX actually plays a role in the regulation of vascular
smooth muscle tone and organ blood perfusion under physi-
ological conditions should not be ruled out. In fact, it should
be borne in mind that (1) measurements of plasma levels of
RLX performed in the past by radioimmunoassay with
heterologous antibodies may have underestimated the actual
physiological levels of this hormone and (2) SMCs, after
explantation from the arterial wall and adaptation to in vitro
culture conditions, may reduce their responsiveness to vaso-
active agents, possibly owing to partial dedifferentiation or
reduction of receptors. This view is also strengthened by the
results of our experiments on [Ca21]i elevations after stimu-
lation of BASMCs with thrombin, a well-known vasoactive
agent, which show that very high, supraphysiological con-
centrations of this agonist are needed to evoke a distinct
response by these cells.
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